Tatyana Gindin

Overview

Tatyana Gindin

Titles

Senior Computational Scientist

Phone
+1 212-851-4654
Email
tg2301@columbia.edu

Lab

Barry Honig

After completing her clinical training in Hematopathology, Tatyana Gindin joined the laboratory of Barry Honig as clinical research fellow in 2012.  She worked on development and application of biophysical and bioinformatics methods to study energetic origins of protein-protein and protein-peptide interactions.  Specific applications included exploration of specificity and improvement of antibodies directed against HIV-1 gp120 envelope protein.  Tatyana's current project is concentrating on using genome-wide protein-protein interaction networks developed in Dr. Honig's laboratory to study cancer regulatory logic in the effort to understand the origins of cancer tumorigenesis and identify novel targets for therapeutics development.

Education History

Fellowship in Hematopathology, Columbia University Medical Center

Residency in Clinical Pathology, Columbia University Medical Center

MD/PhD, Mount Sinai School of Medicine                                                                         Biomedical Sciences

BS, Carnegie Mellon University                                                                                         Biophysics

Publications

Sireci AN, Aggarwal VS, Turk AT, Gindin T, Mansukhani MM, Hsiao SJ. Clinical genomic profiling of a diverse array of oncology specimens at a large academic cancer center: Identification of targetable variants and experience with reimbursement. J Mol Diagn. 2017 Mar;19(2):277-287 

Kwong PD, Chuang G, DeKosky BJ, Gindin T, Georgiev IS, Lemmin T, Schramm CA, Sheng Z, Soto C, Yang AS, Mascola JR, Shapiro L. Antibodyomics: Bioinformatics Technologies for Understanding B Cell Immunity to HIV-1. Immunol Rev. 2017 Jan;275(1):108-128. 

Clark AJ, Gindin T,  Zhang B, Wang L, Abel R, Murreta CS,  Xu F, Bao A, Lu NJ, Zhou T,  Kwong PD, Shapiro L, Honig B, Friesner, RA. Free Energy Perturbation Calculation of Relative Binding Free energy between Broadly Neutralizing Antibodies and the gp120 Glycoprotein of HIV-1. J. Mol. Biol. (2016), http://dx.doi.org/10.1016/j.jmb.2016.11.021 

Zhou T, Lynch RM, Chen L, Acharya P, Wu X, Doria-Rose NA, Joyce MG, Lingwood D, Soto C, Bailer RT, Ernandes MJ, Kong R, Longo NS, Louder MK, McKee K, O'Dell S, Schmidt SD, Tran L, Yang Z, Druz A, Luongo TS, Moquin S, Srivatsan S, Yang Y, Zhang B, Zheng A, Pancera M, Kirys T, Georgiev IS, Gindin T, Peng HP, Yang AS; NISC Comparative Sequencing Program, Mullikin JC, Gray MD, Stamatatos L, Burton DR, Koff WC, Cohen MS, Haynes BF, Casazza JP, Connors M, Corti D, Lanzavecchia A, Sattentau QJ, Weiss RA, West AP Jr, Bjorkman PJ, Scheid JF, Nussenzweig MC, Shapiro L, Mascola JR, Kwong PD. Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell. 2015 Jun 4;161(6):1280-92.